Dataset Information

Prognostic significance of ?2-adrenergic receptor expression in non-small cell lung cancer.

ABSTRACT:

Background

The ?2-Adrenergic receptor (?2-AR) is associated with tumor growth and progression. However, the clinical significance of ?2-AR expression in patients with non-small cell lung cancer (NSCLC) remains unclear.

Methods

Three hundred twenty-eight patients with surgically resected NSCLC were retrospectively investigated. Tumor sections were stained by immunohistochemistry for assessing ?2-AR and Ki-67 expression and microvessel density (MVD), which was using CD34 levels.

Results

?2-AR was positively expressed in 27% of all patients, in 29% of adenocarcinoma (AC) patients, and in 24% of non-AC patients. In AC patients, ?2-AR expression was significantly correlated with lymphatic permeation (r=0.240; P<0.001), vascular invasion (r=0.239; P<0.001), and Ki-67 expression (r=0.175; P=0.009). However, this correlation was not observed in non-AC patients. Positive ?2-AR expression was identified as a negative predictor for worse outcomes in AC patients, particularly in those with stage I tumors. Multivariate analysis confirmed that ?2-AR expression was an independent factor for predicting poor progression-free survival in stage I AC patients (HR=2.220; 95% CI, 1.077-4.573; P=0.031).

Conclusion

?2-AR expression is an independent prognostic factor for early-stage AC patients.

SUBMITTER: Yazawa T

PROVIDER: S-EPMC5126349 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer.

Yazawa Tomohiro T Kaira Kyoichi K Shimizu Kimihiro K Shimizu Akira A Mori Keita K Nagashima Toshiteru T Ohtaki Yoichi Y Oyama Tetsunari T Mogi Akira A Kuwano Hiroyuki H

American journal of translational research 20161115 11

<h4>Background</h4>The β2-Adrenergic receptor (β2-AR) is associated with tumor growth and progression. However, the clinical significance of β2-AR expression in patients with non-small cell lung cancer (NSCLC) remains unclear.<h4>Methods</h4>Three hundred twenty-eight patients with surgically resected NSCLC were retrospectively investigated. Tumor sections were stained by immunohistochemistry for assessing β2-AR and Ki-67 expression and microvessel density (MVD), which was using CD34 levels.<h4> ...[more]

PMID: 27904707

Similar Datasets

Project description:The majority of lung cancers belong to the non-small-cell lung cancer (NSCLC) category, which is linked to a high mortality rate despite significant progress in diagnosis and treatment. Therefore, there is a need for novel prognostic NSCLC biomarkers to improve prognosis which currently remains poor. Recent studies and analyses of gene expression data of NSCLC revealed that high expression of KIAA1522 was significantly associated with poor prognosis and decreased overall survival. We identified 98 patients who underwent radical curative surgical resections or metastasectomy for pulmonary adenocarcinoma and squamous cell carcinoma at our institution or the pathological diagnosis confirmed by our pathologists. Following the latest data, we utilized immunohistochemistry to assess the expression of KIAA1522 and investigated its association with various clinic-demographic parameters, pathological stages, recurrence rates, overall survival, and disease-free survival in patients who achieved complete remission. Notably, there were no significant differences in the expression profiles of KIAA1522 between adenocarcinoma and squamous cell carcinoma samples (p=0.6). Survival analysis was conducted using log-rank tests and a multivariate Cox proportional hazard model. Of the 98 samples, 54 (55.1%) exhibited high expression of KIAA1522, and patients with high KIAA1522 expression had a significantly shorter overall survival than the low-expression group (p=0.01). Multivariate Cox proportional hazard models in which metastatic patients were included revealed that along with older age, higher TNM stage (tumor, node, metastasis system), and Eastern Cooperative Oncology Group (ECOG) performance status, high expression of KIAA1522 served as an independent prognostic factor. A high expression profile was not significantly associated with relapses in those whose complete remission had been achieved. Still, those patients with high expression of KIAA1522 tended to exhibit a shorter disease-free survival rate. In conclusion, our findings suggest that KIAA1522 expression is an independent factor for predicting overall survival and may serve as a valuable prognostic indicator for relapse and disease-free survival in NSCLC patients.